Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism

Lupus

Volumn 17, Issue 2, 2008, Pages 132-134

  Boonsrirat, U ^a   Angsuthum, S ^a   Vannaprasaht, S ^a   Kongpunvijit, J ^a   Hirankarn, N ^b   Tassaneeyakul, W ^a   Avihingsanon, Yingyos ^a,b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

6 mercaptopurine; Genetic polymorphism; Myelosuppression; Pharmacogenetics; Systemic lupus erythematosus; Thiopurine S methyltransferase

Indexed keywords

AMPHOTERICIN B; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYCHLOROQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; ALLELE; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; CRYPTOCOCCAL MENINGITIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG WITHDRAWAL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULOSCLEROSIS; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY BIOPSY; LEG EDEMA; NEPHROTIC SYNDROME; PANCYTOPENIA; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TYPHLITIS;

ADULT; ALLELES; AZATHIOPRINE; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOPENIA; LUPUS ERYTHEMATOSUS, SYSTEMIC; METHYLTRANSFERASES; MUTATION; POLYMORPHISM, GENETIC;

EID: 40449092560     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307085255     Document Type: Article

References (10)

1. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149-154.
2. Srimartpirom S, Tassaneeyakul W, Kukongviriyapan V, Tassaneeyakul W. Thiopurine S-methyltransferase genetic polymorphism in the Thai population. Br J Clin Pharmacol 2004; 58: 66-70.
3. Ford LT, Berg JD. Determination of thiopurine S-methyltransferase activity in erythrocytes using 6-thioguanine as substrate and a non-extraction liquid chromatographic technique. J Chromatogr B Anal Technol Biomed Life Sci 2003; 798: 111-115.
4. Coulthard S, Hogarth L. The thiopurines: an update. Invest New Drugs 2005; 23: 523-532.
5. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999; 8: 371-376.
6. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999; 9: 37-42.
7. Decaux G, Horsmans Y, Houssiau F, Desager JP. High 6-thioguanine nucleotide levels and low thiopurine methyltransferase activity in patients with lupus erythematosus treated with azathioprine. Am J Ther 2001; 8: 147-150.
8. Naughton MA, Battaglia E, O'Brien S, Walport MJ, Botto M. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology 1999; 38: 640-644.
9. Okada Y, Nakamura K, Kodama T et al. Thiopurine methyltransferase genotype and phenotype status in Japanese patients with systemic lupus erythematosus. Biol Pharm Bull 2005; 28: 2117-2119.
10. Morales A, Salguti S, Miao CL, Lewis JD. Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 380-385.